(R)-2-chloro-1-(2,3-dihydroxy-2-methyl)-propyl-4-nitroimidazole | 681490-91-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (R)-2-chloro-1-(2,3-dihydroxy-2-methyl)-propyl-4-nitroimidazole
• 英文别名: (R)-3-(2-Chloro-4-nitro-1H-imidazol-1-yl)-2-methylpropane-1,2-diol；(2R)-3-(2-chloro-4-nitroimidazol-1-yl)-2-methylpropane-1,2-diol
• CAS: 681490-91-5
• 化学式: C₇H₁₀ClN₃O₄
• 分子量: 235.627
• InChiKey: UEYAJHCNNXRAIQ-SSDOTTSWSA-N

物化性质

• 沸点：
  515.1±60.0 °C(Predicted)
• 密度：
  1.61±0.1 g/cm3(Predicted)
• 溶解度：
  溶于氯仿、DCM

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (R)-2-chloro-1-(2,3-dihydroxy-2-methyl)-propyl-4-nitroimidazole 在 吡啶 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 乙酸乙酯 为溶剂， 反应 4.0h， 生成 (R)-2-氯-1-(2-甲基环氧乙烷-2-基甲基)-4-硝基咪唑
  参考文献：
  名称：

  Synthesis of new generation triazolyl- and isoxazolyl-containing 6-nitro-2,3-dihydroimidazooxazoles as anti-TB agents: in vitro, structure–activity relationship, pharmacokinetics and in vivo evaluation

  摘要：

  有前途的硝基咪唑噁唑骨架提供了另一种新颖的三唑基含有的6-硝基-2,3-二氢咪唑噁唑作为抗结核病的先导化合物。

  DOI：

  10.1039/c5ob00054h
• 作为产物：
  描述：

  (吡咯烷基亚甲基)环己烷 在 potassium carbonate 、 盐酸 、 sodium sulfate 作用下， 以 甲醇 、 水 为溶剂， 反应 3.0h， 以97%的产率得到(R)-2-chloro-1-(2,3-dihydroxy-2-methyl)-propyl-4-nitroimidazole
  参考文献：
  名称：

  Synthesis of new generation triazolyl- and isoxazolyl-containing 6-nitro-2,3-dihydroimidazooxazoles as anti-TB agents: in vitro, structure–activity relationship, pharmacokinetics and in vivo evaluation

  摘要：

  有前途的硝基咪唑噁唑骨架提供了另一种新颖的三唑基含有的6-硝基-2,3-二氢咪唑噁唑作为抗结核病的先导化合物。

  DOI：

  10.1039/c5ob00054h

文献信息

• [EN] 6-NITRO-2,3-DIHYDROIMIDAZO[2,1-b]OXAZOLES AND A PROCESS FOR THE PREPARATION THEREOF<br/>[FR] 6-NITRO-2,3-DIHYDROIMIDAZO[2,1-B]OXAZOLES ET LEUR PROCÉDÉ DE PRÉPARATION
  申请人：COUNCIL SCIENT IND RES

  公开号：WO2015049693A1

  公开（公告）日：2015-04-09

  The present invention relates to newer generation of triazoles, tetrazoles, isoxazoles, urea and sulphonamide functionalities containing 6-nitro-2, 3-dihydronitroimidazooxazoles agents of formula 1, their method of preparation, and their use as drugs for treating Mycobacterium tuberculosis,MDR-TB and XDR-TB either alone or in combination with other anti-tubercular agents. In the present invention, new generation 6-nitro-2, 3-dihydronitroimidazooxazoles agents also show acceptable pharmacokinetic properties and synergistic or additive effects with known anti-tubercular drugs.

  本发明涉及新一代三唑类、四唑类、异噁唑类、尿素和磺胺类功能团的含有6-硝基-2,3-二氢硝基咪唑噁唑类化合物的制备方法，以及它们作为治疗结核分枝杆菌、耐药结核分枝杆菌和极耐药结核分枝杆菌的药物的用途，可以单独使用，也可以与其他抗结核药物联合使用。在本发明中，新一代6-硝基-2,3-二氢硝基咪唑噁唑类化合物还表现出可接受的药代动力学性质，并与已知的抗结核药物呈现协同或加成效应。
• [EN] SUBSTITUTED 1,2,3-TRIAZOL-1-YL-METHYL-2,3-DIHYDRO-2-METHYL-6-NITROIMIDAZO[2,1-B]OXAZOLES AS ANTI-MYCOBACTERIAL AGENTS AND A PROCESS FOR THE PREPARATION THEREOF<br/>[FR] 1,2,3-TRIAZOL-1-YL-MÉTHYL-2,3-DIHYDRO -2-MÉTHYL-6-NITROIMIDAZO [2,1-B] OXAZOLES SUBSTITUÉS COMME AGENTS ANTI-MYCOBACTÉRIENS ET PROCÉDÉ DE PRÉPARATION ASSOCIÉ
  申请人：COUNCIL SCIENT IND RES

  公开号：WO2016063298A1

  公开（公告）日：2016-04-28

  The present invention relates to new generation of triazole functionality containing 6-nitro-2,3-dihydroimidazooxazole agents for general formula I, their method of preparation and their use as drugs for treatment of tuberculosis, MDR-TB and XDR-TB either alone or in combination with other anti-tubercular agents. In general formula l, X is selected from a group (CH2)nor a direct bond, where n is any number from 1-6,Y is selected from O, S or direct bond, R1 is selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, biaryl, substituted biaryl, heterocyclic and substituted heterocyclic, wherein the substituted heterocyclic is selected from any of the following rings consisting of piperazinyl, morpholinyl, piperidyl, pyridyl, triazolyl, triazinyl, pyrimidinyl, pyridazinyl, oxazolyl, furanyl, benzofuranyl, thiophenyl, pyrrolyl, imidazoyl, thiazoyl, quinolinyl, isoquinolinyl, benzooxazolyl and benzothiazolyl and the substitution on aryl and biaryl is selected from the group consisting of F, CI, Br, I, CF3, OCF3, OR11, NO2 and alkyl chain from C1 to C14, wherein R11 is selected from the group consisting of H, alkyl, phenyl and substituted phenyl.

  本发明涉及一种新一代三唑功能团含有6-硝基-2,3-二氢咪唑噁唑醇类化合物的通式I，其制备方法以及它们作为治疗结核病、耐多药结核病和极耐多药结核病的药物的用途，可以单独使用或与其他抗结核药物联合使用。在通式I中，X从(CH2)nor直接键中选择，其中n是1-6之间的任意数字，Y从O、S或直接键中选择，R1从H、烷基、取代烷基、芳基、取代芳基、联苯基、取代联苯基、杂环基和取代杂环基中选择，其中取代杂环基从以下任一环中选择，包括哌嗪基、吗啉基、哌啶基、吡啶基、三唑基、三嗪基、嘧啶基、吡啶嗪基、噁唑基、呋喃基、苯并呋喃基、噻吩基、吡咯基、咪唑基、噻唑基、喹啉基、异喹啉基、苯噁唑基和苯噻唑基，芳基和联苯基上的取代基选择自F、Cl、Br、I、CF3、OCF3、OR11、NO2和碳数为C1至C14的烷基链，其中R11从H、烷基、苯基和取代苯基中选择。
• 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles
  申请人：Tsubouchi Hidetsugu

  公开号：US20060094767A1

  公开（公告）日：2006-05-04

  The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: wherein R 1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R 2 represents a group —OR 3 or the like, and R 3 represents a hydrogen atom, C1-C6 alkyl group or the like, or R 1 and —(CH 2 ) n R 2 may bind to each other together with carbon atoms adjacent thereto through nitrogen atoms so as to form a spiro ring represented by the general formula (H): wherein R 41 is hydrogen, C1-C6 alkyl group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis , multi-drug-resistant Mycobacterium tuberculosis , and atypical acid-fast bacteria.

  本发明提供了一种2,3-二氢-6-硝基咪唑并[2,1-b]噁唑化合物，其通式如下：其中，R1代表氢原子或C1-C6烷基，n代表0到6的整数，R2代表—OR3或类似的基团，R3代表氢原子、C1-C6烷基或类似的基团，或者R1和—(CH2)nR2可以通过相邻的碳原子通过氮原子结合在一起形成一个螺环，其通式为（H）：其中，R41为氢、C1-C6烷基或类似的基团。该化合物对结核分枝杆菌、多药耐药结核分枝杆菌和非典型酸性快速细菌具有优异的杀菌作用。
• 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US07262212B2

  公开（公告）日：2007-08-28

  The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: wherein R1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R2 represents a group —OR3 or the like, and R3 represents a hydrogen atom, C1-C6 alkyl group or the like, or R1 and —(CH2)nR2 may bind to each other together with carbon atoms adjacent thereto through nitrogen atoms so as to form a spiro ring represented by the general formula (H): wherein R41 is hydrogen, C1-C6 alkyl group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria.

  本发明提供一种由以下通式表示的2,3-二氢-6-硝基咪唑并[2,1-b]噁唑化合物：其中R1代表氢原子或C1-C6烷基，n代表0到6的整数，R2代表-OR3基团或类似基团，R3代表氢原子、C1-C6烷基或类似基团，或R1和-(CH2)nR2可以与相邻的碳原子通过氮原子结合在一起，形成由通式（H）表示的螺环：其中R41是氢、C1-C6烷基或类似基团。该化合物对结核分枝杆菌、多药耐药结核分枝杆菌和非典型酸性快速菌具有优异的杀菌作用。
• 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP1555267A1

  公开（公告）日：2005-07-20

  The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: wherein R1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R2 represents a group -OR3 or the like, and R3 represents a hydrogen atom, C1-C6 alkyl group or the like, or R1 and -(CH2)nR2 may bind to each other together with carbon atoms adjacent thereto through nitrogen atoms so as to form a spiro ring represented by the general formula (H): wherein R41 is hydrogen, C1-C6 alkyl group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and a typical acid-fast bacteria.

  本发明提供了由以下通式代表的 2，3-二氢-6-硝基咪唑并[2，1-b]恶唑化合物： 其中R1代表氢原子或C1-C6烷基，n代表0至6的整数，R2代表基团-OR3或类似基团，R3代表氢原子、C1-C6烷基或类似基团，或者R1和-(CH2)nR2可以通过氮原子与相邻的碳原子相互结合，从而形成通式(H)代表的螺环： 其中 R41 为氢、C1-C6 烷基或类似基团。本化合物对结核分枝杆菌、多重耐药结核分枝杆菌和典型的耐酸细菌有很好的杀菌作用。